MedTrace Logo

Evolocumab in STEMI

NCT06081803 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 166

Last updated 2025-06-19

No results posted yet for this study

Summary

The goal of this clinical trial is to compare the size of myocardial infarct between evolocumab and control groups in patients with ST segment elevation myocardial infarction who undergoing primary percutaneous coronary intervention(PCI). All study participants will undergo a cardiac MRI 4 weeks after primary reperfusion. The evolocumab group will receive 420 mg before PCI via subcutaneous injection.

Conditions

  • ST Elevation Myocardial Infarction

Interventions

DRUG

Repatha®

Repatha® 140mg x 3 pens subcutaneous injection

Sponsors & Collaborators

  • Samsung Medical Center

    collaborator OTHER

  • National Health Insurance Service Ilsan Hospital

    collaborator OTHER

  • Chonnam National University Hospital

    collaborator OTHER

  • Daegu Catholic University Medical Center

    collaborator OTHER

  • Catholic University of Korea Eunpyeong St. Mary's Hospital

    collaborator UNKNOWN

  • Sejong General Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-05
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06081803 on ClinicalTrials.gov